{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:32:25Z","timestamp":1794022345939,"version":"4.8.0"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>Outcomes for high-risk neuroblastoma have improved with the addition of antidisialoganglioside (GD2) antibody-mediated immunotherapy to multimodality therapy. Urticaria is an expected side effect of anti-GD2 immunotherapy. Rarely, despite maximal use of antihistamines and H2 receptor antagonists, refractory urticaria can result in impaired quality of life, and delays or discontinuation of immunotherapy. The anti-IgE monoclonal antibody, omalizumab, is approved for the treatment of asthma and chronic spontaneous urticaria. We successfully managed grade 3, naxitamab-related urticaria refractory to standard management in 2 patients using omalizumab, allowing for continued anti-GD2 immunotherapy. Omalizumab did not impact antitumor activity or immunogenicity of naxitamab.<\/jats:p>","DOI":"10.1097\/mph.0000000000002939","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T21:26:23Z","timestamp":1724448383000},"page":"e531-e533","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Omalizumab for Treatment of Anti-GD2 Antibody-related Urticaria"],"prefix":"10.1097","volume":"46","author":[{"given":"Rachel","family":"Glincher","sequence":"first","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lentini-Rivera","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latisha","family":"Andre Jones","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"D\u2019Andrea","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Durney","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Kasper","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichih","family":"Lin","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Shrager","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[{"name":"Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Lacouture","sequence":"additional","affiliation":[{"name":"Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-1726","authenticated-orcid":false,"given":"Shakeel","family":"Modak","sequence":"additional","affiliation":[{"name":"Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","article-title":"Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission","volume":"30","author":"Cheung","year":"2012","journal-title":"J Clin Oncol"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jamaoncol.2018.4005","article-title":"Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma: a phase 1 clinical trial","volume":"4","author":"Kushner","year":"2018","journal-title":"JAMA Oncol"},{"key":"R5-20250804","first-page":"e1627","article-title":"Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and\/or relapsed high-risk neuroblastoma: management of adverse events","volume":"6","author":"Mora","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-200161020-00008","article-title":"Omalizumab","volume":"61","author":"Easthope","year":"2001","journal-title":"Drugs"},{"key":"R7-20250804","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","volume":"2014","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14712598.2018.1438406","article-title":"Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic\/spontaneous urticaria: a systematic review of \u2018real-world\u2019 evidence","volume":"18","author":"Bernstein","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"R12-20250804","first-page":"SIOP19","article-title":"Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: preliminary results of\u201cHITS\u201d Pilot\/Phase II Study","volume":"66","author":"Kushner","year":"2019","journal-title":"Pediatr Blood Cancer"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:02:07Z","timestamp":1754337727000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002939","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"2024-05-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}